Riddell David R, Zhou Hua, Atchison Kevin, Warwick Helen K, Atkinson Peter J, Jefferson Julius, Xu Lin, Aschmies Suzan, Kirksey Yolanda, Hu Yun, Wagner Erik, Parratt Adrienne, Xu Jane, Li Zhuting, Zaleska Margaret M, Jacobsen J Steve, Pangalos Menelas N, Reinhart Peter H
Discovery Neuroscience, Wyeth Research, CN8000, Princeton, New Jersey 08543, USA.
J Neurosci. 2008 Nov 5;28(45):11445-53. doi: 10.1523/JNEUROSCI.1972-08.2008.
Inheritance of the apoE4 allele (epsilon4) increases the risk of developing Alzheimer's disease; however, the mechanisms underlying this association remain elusive. Recent data suggest that inheritance of epsilon4 may lead to reduced apoE protein levels in the CNS. We therefore examined apoE protein levels in the brains, CSF and plasma of epsilon2/2, epsilon3/3, and epsilon4/4 targeted replacement mice. These apoE mice showed a genotype-dependent decrease in apoE levels; epsilon2/2 >epsilon3/3 >epsilon4/4. Next, we sought to examine the relative contributions of apoE4 and apoE3 in the epsilon3/4 mouse brains. ApoE4 represented 30-40% of the total apoE. Moreover, the absolute amount of apoE3 per allele was similar between epsilon3/3 and epsilon3/4 mice, implying that the reduced levels of total apoE in epsilon3/4 mice can be explained by the reduction in apoE4 levels. In culture medium from epsilon3/4 human astrocytoma or epsilon3/3, epsilon4/4 and epsilon3/4 primary astrocytes, apoE4 levels were consistently lower than apoE3. Secreted cholesterol levels were also lower from epsilon4/4 astrocytes. Pulse-chase experiments showed an enhanced degradation and reduced half-life of newly synthesized apoE4 compared with apoE3. Together, these data suggest that astrocytes preferentially degrade apoE4, leading to reduced apoE4 secretion and ultimately to reduced brain apoE levels. Moreover, the genotype-dependent decrease in CNS apoE levels, mirror the relative risk of developing AD, and suggest that low levels of total apoE exhibited by epsilon4 carriers may directly contribute to the disease progression, perhaps by reducing the capacity of apoE to promote synaptic repair and/or Abeta clearance.
载脂蛋白E4等位基因(ε4)的遗传会增加患阿尔茨海默病的风险;然而,这种关联背后的机制仍然难以捉摸。最近的数据表明,ε4的遗传可能导致中枢神经系统中载脂蛋白E蛋白水平降低。因此,我们检测了ε2/2、ε3/3和ε4/4靶向替代小鼠的大脑、脑脊液和血浆中的载脂蛋白E蛋白水平。这些载脂蛋白E小鼠的载脂蛋白E水平呈现出基因型依赖性降低;ε2/2>ε3/3>ε4/4。接下来,我们试图研究ε3/4小鼠大脑中载脂蛋白E4和载脂蛋白E3的相对贡献。载脂蛋白E4占总载脂蛋白E的30 - 40%。此外,ε3/3和ε3/4小鼠每个等位基因的载脂蛋白E3绝对量相似,这意味着ε3/4小鼠总载脂蛋白E水平的降低可以用载脂蛋白E4水平的降低来解释。在来自ε3/4人星形细胞瘤或ε3/3、ε4/4和ε3/4原代星形胶质细胞的培养基中,载脂蛋白E4水平始终低于载脂蛋白E3。ε4/4星形胶质细胞分泌的胆固醇水平也较低。脉冲追踪实验表明,与载脂蛋白E3相比,新合成的载脂蛋白E4降解增强且半衰期缩短。总之,这些数据表明星形胶质细胞优先降解载脂蛋白E4,导致载脂蛋白E4分泌减少,最终导致大脑载脂蛋白E水平降低。此外,中枢神经系统中载脂蛋白E水平的基因型依赖性降低反映了患阿尔茨海默病的相对风险,并表明ε4携带者表现出的低总载脂蛋白E水平可能直接促进疾病进展,可能是通过降低载脂蛋白E促进突触修复和/或清除β淀粉样蛋白的能力。